Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

New targeted drugs for metastatic renal cell carcinoma

ECCO 15 - ESMO 34

20 - 24 Sep 2009

Published: 25 Sep 2009

Views: 12070

Rating:

Save

Dr Joaquim Bellmunt - Section Chief, Solid Tumor Oncology, Hospital del Mar, Barcelona, Spain

Expert interview with Dr Joaquim Bellmunt MD PhD conducted by Prof Gordon McVie

Categories:
Hepatobiliary pancreatic

Related Videos

Palliative radiotherapy for symptomatic hepatocellular carcinoma improves...

Prof Laura Dawson - University of Toronto, Toronto, Canada

Palliative radiotherapy for symptomatic hepatocellular carcinoma improves survival in HCC or liver metastases ( Prof Laura Dawson - University of Toronto, Toronto, Canada )

Stereotactic body radiation therapy (SBRT) followed by sorafenib in HCC...

Prof Laura Dawson - University of Toronto, Toronto, Canada

Stereotactic body radiation therapy (SBRT) followed by sorafenib in HCC improves OS ( Prof Laura Dawson - University of Toronto, Toronto, Canada )

Intraoperative Radiotherapy

Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal

Intraoperative Radiotherapy ( Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal )

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell...

Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy ( Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA )

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable...

Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )

Lenvatinib remains standard of care for first-line therapy in advanced...

Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )

Perioperative nivolumab did not improve RFS in RCC patients at high risk for...

Dr Mohamad Allaf - The Johns Hopkins Hospital, Baltimore, USA

Perioperative nivolumab did not improve RFS in RCC patients at high risk for recurrence ( Dr Mohamad Allaf - The Johns Hopkins Hospital, Baltimore, USA )

Physical activity improves quality of life for patients with pancreatic cancer

Dr Mike Cusnir - Mount Sinai Medical Center, Florida, USA

Physical activity improves quality of life for patients with pancreatic cancer ( Dr Mike Cusnir - Mount Sinai Medical Center, Florida, USA )

Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer...

Dr Pamela Kunz - Yale Cancer Center, New Haven, USA

Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer PFS than temozolomide alone ( Dr Pamela Kunz - Yale Cancer Center, New Haven, USA )

More from ecancer